Skip to main content
SpringerLink
Log in

Platelet Activation and Aggregation : Rationale for Combining Antithrombotic Drugs

  • Chapter
Antithrombotics

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 126))

Abstract

Exposure of the GPIIb/IIIa receptor, the final common pathway of aggregation, can be obtained via different mechanisms and by different stimuli. The synthesis of thromboxane A2 can be blocked by aspirin and thromboxane synthase inhibitors, whereas its activity can be blocked by antagonists or by combined synthase inhibitors/antagonists. Agents that increase cAMP/cGMP prevent the exposure of the GPIIb/IIIa receptor and by also inhibiting the release reaction, are likely to have a broader spectrum of activity than pure GPIIb/IIIa receptor antagonists.

Combination of antithrombotic drugs has the possible advantage that different pathways of aggregation are affected, that the release of growth factors and/or procoagulants could be inhibited, that the presence of synergism will increase the efficacy and that other (mainly vascular) effects could be modulated. A multitude of in vitro and in vivo experimental data prove the superiority of such a combination and careful analysis of the clinical studies point also in that direction.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Radomski, M.W., Palmer, R.M.J. and Moncada, S. (1987) ‘The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide’, Br. J. Pharmac. 91, 639–646.

    Article  Google Scholar 

  2. Baumgartner, H.R. and Born, G.V.R. (1960) ‘Effects of 5-hydroxytryptamine on platelet aggregation’, Nature 218, 137–141.

    Article  Google Scholar 

  3. Heras, M., Chesebro, J.H., Penny, W.J., Bailey, K.R., Badimon, L. and Fuster, V. (1989) ‘Effects of thrombin inhibition on the development of acute platelet thrombus deposition during angioplasty in pigs’, Circulation 79, 657–665.

    Article  PubMed  CAS  Google Scholar 

  4. Gachet, C., Cazenave, J.-P., Ohlmann, P., Bouloux, C., Defreyn, G., Driot, F. and Maffrand, J.-P. (1990) ‘The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1’, Biochem. Pharmacol. 40, 2683–2687.

    Article  PubMed  CAS  Google Scholar 

  5. Braquet, P., Touqui, L., Shen, T.Y. and Vargaftig, B.R. (1987) ‘Perspectives in platelet activating factor research’, Pharmacol. Rev. 39, 97–145.

    PubMed  CAS  Google Scholar 

  6. Adamus, W.S., Huer, H., Meade, C.J., Frey, G. and Brecht, H.M. (1988) ‘Inhibitory effect of oral WEB 2086, a novel selective PAF-acether antagonist, on ex vivo platelet aggregation’, Eur. J. Clin. Pharmacol. 35, 237–240.

    Article  PubMed  CAS  Google Scholar 

  7. Reilly, I.A.G. and Fitzgerald, G.A. (1987) ‘Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs’, Blood 69, 180–186.

    PubMed  CAS  Google Scholar 

  8. Gresele, P., Deckmyn, H., Nenci, G.G. and Vermylen, J. (1991) ‘Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders’, Trends Pharmacol. Sci. 12, 160–163.

    Article  Google Scholar 

  9. Kyrle, P.A., Eichler, H.G., Jäger, U. and Lechner, K. (1987) ‘Inhibition of prostacyclin and thromboxane A2 generation by low-dose aspirin at the site of plug formation’, Circulation 75, 1025–1029.

    Article  PubMed  CAS  Google Scholar 

  10. Moncada, S. and Korbut, R. (1978) ‘Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin’, Lancet, i, 1286–1289.

    Article  Google Scholar 

  11. Deckmyn, H., Van Houtte, E., Verstraete, M. and Vermylen, J. (1983) ‘Manipulation of the local thromboxane and prostacyclin balance in vivo by the antithrombotic compounds dazoxiben, acetylsalicylic acid and nafazatrom’, Biochem. Pharmacol. 32, 2757–2762.

    Article  PubMed  CAS  Google Scholar 

  12. Gresele, P., Arnout, J., Deckmyn, H., Huybrechts, E., Pieters, G. and Vermylen, J. (1987) ‘Role of proaggre-gatory and anti-aggregatory prostaglandins in hemosta-sis’, J. Clin. Invest. 80, 1435–1445.

    Article  PubMed  CAS  Google Scholar 

  13. Nowak, J. and Fitzgerald, G.A. (1989) ‘Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in man’, J. Clin. Invest. 83, 380–385.

    Article  PubMed  CAS  Google Scholar 

  14. Gresele, P., Deckmyn, H., Arnout, J., Nenci, G.G. and Vermylen, J. (1989) ‘Characterization of N, N’-bis (3picolyl)-4(methoxy-isophtalamide (Picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets’, Thromb. Haemostasis 61, 479–484.

    CAS  Google Scholar 

  15. De Clerck, F., Beetens, J., De Chaffoy De Courcelles, D., Freyne, E. and Janssen, P.A.J. (1989) ‘R68070: thromboxane synthase inhibition and thromboxane A2/-prostaglandin endoperoxide receptor blockade combined in one molecule - I, Biochemical profile in vitro’, Thromb. Haemostasis 61, 35–42.

    Google Scholar 

  16. Hoet, B., Falcon, C., De Reys, S., Arnout, J., Deckmyn, H. and Vermylen, J. (1990) ‘R68070, a combined thromboxane-endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: comparison with aspirin’, Blood 75, 646–653.

    PubMed  CAS  Google Scholar 

  17. Hoet, B., Arnhout, J., Van Geet, C., Deckmyn, H., Verhaeghe, R. and Vermylen, J. (1990) ‘Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma ß-thromboglobulin levels in patients with documented peripheral arterial disease’, Thromb. Haemostasis 64, 87–90.

    CAS  Google Scholar 

  18. Radomski, M.W., Palmer, R.M.J. and Moncada, S. (1990) ‘Characterization of the L-arginine: nitric oxide pathway in human platelets’, Br. J. Pharmac. 101, 325–328.

    Article  CAS  Google Scholar 

  19. Radomski, M.W., Palmer, R.M.J. and Moncada, S. (1990) ‘An L-arginine/nitric oxide pathway present in human platelets regulates aggregation’, Proc. Natl. Acad. Sci. USA. 87, 5193–5197.

    Article  PubMed  CAS  Google Scholar 

  20. Bult, H., Fret, H.R.L., Jordaens, F.H. and Herman, A.G. (1991) ‘Dipyridamole potentiates platelet inhibition by nitric oxide’, Thromb. Haemostasis, in press.

    Google Scholar 

  21. Coller, B.S. (1985) ‘A new murine monoclonal antibody reports an activation-dependent change in the confirmation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex’, J. Clin. Invest. 76, 101–108.

    Article  PubMed  CAS  Google Scholar 

  22. Plow, E.F., Pierschbacher, M.D., Ruoslahti, E., Marguerie, G.A. and Ginsberg, M.H. (1985) ‘The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets’, Proc. Natl. Acad. Sci. USA. 82, 8057–8061.

    Article  PubMed  CAS  Google Scholar 

  23. Haverstick, D.M., Cowan, J.F., Yamada, K.M. and Santoro, S.A. (1985) ‘Inhibition of platelet adhesion to fibronectin, fibrinogen and von Willebrand factor substrates by a synthetic tetrapeptide derived from the cell-binding domain of fibronectin’, Blood 66, 946–952.

    PubMed  CAS  Google Scholar 

  24. Huang, T-F., Holt, J.C., Lukasiewicz, H. and Niewiarowski, S. (1987) ‘Trigramin: a low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb-IIIa complex’, J. Biol. Chem. 262, 16157–16163.

    PubMed  CAS  Google Scholar 

  25. Gan, Z-R., Gould, R.J., Jacobs, J.W., Friedman, P.A. and Polokoff, M.A. (1988) ‘Echistatin a potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus’, J. Biol. Chem. 263, 19827–19832.

    PubMed  CAS  Google Scholar 

  26. Dennis, M.S., Henzel, W.J. Pitti, R.M., Lipari, M.T., Napier, M.A., Deisher, T.A., Bunting, S. and Lazarus, R.A. (1990) ‘Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms. Evidence for a family of platelet-aggregation inhibitors’, Proc. Natl. Acad. Sci. USA. 87, 2471–2475.

    Article  PubMed  CAS  Google Scholar 

  27. Coller, B.S., Folts, J.D., Smith, S.R. and Scudder, L.E. (1987) ‘Abolition of in vivo platelet thrombus formation with monoclonal antibodies to the platelet GPIIb/IIIa receptor: correlation with platelet aggregation and bleeding time’, Thromb. Haemostasis 58, 244.

    Google Scholar 

  28. Hanson, S.R., Harker, L.A. and Bjornsson, T.D. (1985) ‘Effect of platelet-modifying drugs on arterial thromboembolism in baboons: aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition’ J. Clin. Invest. 75, 1591–1599.

    Article  PubMed  CAS  Google Scholar 

  29. Cazenave, J-P., Packham, M.A., Guccione, M.A. and Mustard, J.F. (1973) ‘Effects of penicillin G on platelet aggregation, release and adherence to collagen’ Proc. Soc. Exp. Biol. Med. 142, 159–166.

    PubMed  CAS  Google Scholar 

  30. Harker, L.A. and Fuster, V. (1986) ‘Pharmacology of platelet inhibitors’, J. Am. Coll. Cardiol. 8 (suppl. B), 21B–32B.

    Article  PubMed  CAS  Google Scholar 

  31. Moncada, S. (1982) ‘Biological importance of prostacyclin’, Br. J. Pharmac. 76, 3–31.

    Article  CAS  Google Scholar 

  32. Moncada, S., Palmer, R.M.J. and Higgs, E.A. (1991) ‘Nitric oxide: physiology, pathophysiology and pharmacology’, Pharmacol. Rev., in press.

    Google Scholar 

  33. Quadt, J.F.A., Voss, R. and Ten Hoor, F. (1982) ‘Prostacyclin production of the isolated pulsatingly perfused rat aorta’, J. Pharmacol. Method 7, 263–270.

    Article  CAS  Google Scholar 

  34. Pohl, U., Holtz, J., Busse, R. and Bassenge, E. (1986) ‘Crucial role of the endothelium in the vasodilator response to increased flow in vivo’, Hypertension 8, 37–44.

    Article  PubMed  CAS  Google Scholar 

  35. Pohl, U., Herlan, K., Huang, A. and Bassenge, E. (1990) ‘EDRF-mediated, shear-induced dilation opposes myogenic vasocontriction’, Am. J. Physiol., in press.

    Google Scholar 

  36. Manson, J.E., Grobsee, D.E., Stampfer, M.J., Taylor, J.O., Goldhaber, S.Z., Gaziano, M., Ridker, P.M., Buring, J.E. and Hennekens, C.H. (1990) ‘Aspirin in the primary prevention of angina pectoris in a randomized trial of United States Physicians’, Am. J. Med. 89, 772–776.

    Article  PubMed  CAS  Google Scholar 

  37. Yang, Z., Stulz, P., Von Segesser, L., Bauer, E., Turina, M. and Luscher, T.F. (1991) ‘Different interactions of platelets with arterial and venous coronary bypass vessels’, Lancet 337, 939–943.

    Article  PubMed  CAS  Google Scholar 

  38. Antiplatelet Trialists’ Collaboration (1988) ‘Secondary prevention of vascular disease by prolonged antiplatelet treatment’, Br. Med. J. 296, 320–331.

    Article  Google Scholar 

  39. Stein, B., Fuster, V., Israel, D.H., Cohen, M., Badimon, L., Badimon, J.J. and Chesebro, J.H. (1989) ‘Platelet inhibitor agents in cardiovascular disease an update’, J. Am. Coll. Cardiol. 14, 813–836.

    Article  PubMed  CAS  Google Scholar 

  40. Verstraete, M. (1990) ‘Les anti-aggrégants en 1990’, La Revue de Med. Int. 11, 209–215.

    Article  CAS  Google Scholar 

  41. Sze, P.C., Reitman, D., Pincus, M.M., Sacks, H.S. and Chalmers, T.C. (1988) ‘Antiplatelet agents in the secondary prevention of stroke’, Stroke 19, 436–442.

    Article  PubMed  CAS  Google Scholar 

  42. Yusuf, S., Sleight, P., Held, P. and McMahon, S. (1990) ‘Routine medical management of acute myocardial infarction. Lessons from overvieuws of recent randomized controlled trials’, Circulation 82 (suppl II), II117–II134.

    PubMed  CAS  Google Scholar 

  43. Reitman, D., Sacks, H.S., Chalmers, T.C., Sze, P. and Pincus, M.D. (1988) ‘Letter to the Editor’, Stroke 19, 1447–1448.

    Article  Google Scholar 

Download references

Authors
  1. A. G. Herman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Antwerp (UIA)., Antwerp, Belgium

    Arnold G. Herman (Professor of Pharmacology) (Professor of Pharmacology)

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Herman, A.G. (1991). Platelet Activation and Aggregation : Rationale for Combining Antithrombotic Drugs. In: Herman, A.G. (eds) Antithrombotics. Developments in Cardiovascular Medicine, vol 126. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-3484-2_1

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-3484-2_1

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-5540-6

  • Online ISBN: 978-94-011-3484-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation